Inhibits cholesterol biosynthesis at the level of 2,3-oxidosqualene cyclase (OSC). Blocks OSC and cholesterol synthesis in HepG2 cells in the nanomolar range. A novel lipid lowering agent.
Product Details
| MW: | 564.4 |
| |
| CAS: | 189197-69-1 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Appearance: | Pale yellow solid. |
| |
| Solubility: | Soluble in water (25 mg/ml) |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | Ambient |
| |
| Use/Stability: | Store, as supplied, at room temperature for up to 1 year. Store solutions at -20°C for up to 3 months. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Induction of CYP3A by 2,3-oxidosqualene:lanosterol cyclase inhibitors is mediated by an endogenous squalene metabolite in primary cultured rat hepatocytes: S. D. Shenoy, et al.; Mol. Pharmacol.
65, 1302 (2004),
Abstract;
Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin: O. H. Morand, et al.; J. Lipid. Res.
38, 373 (1997),
Abstract;
